Ryvu Therapeutics participates in the upcoming 13th Annual LifeSci Partners Corporate Access Event

Krakow, Poland – January 4, 2024 – Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced that Vatnak Vat-Ho, Chief Business Officer of Ryvu Therapeutics will join the 13th Annual LifeSci Partners Corporate Access Event, taking place on January 8-10, 2024, in San Francisco, California.

Vatnak will be diving into discussions with potential investors and strategic partners. He will also engage with the banking community to showcase the innovative strides Ryvu is making in the biotech sector and to explore collaborations that drive us toward the next groundbreaking advancements.